25 results on '"Monroy-Iglesias, Maria J."'
Search Results
2. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England
- Author
-
Fox, Louis, Monroy-Iglesias, Maria J., Aggarwal, Ajay, Haire, Kate, Purushotham, Arnie, Spicer, James, Papa, Sophie, Rigg, Anne, Dolly, Saoirse, Sullivan, Richard, and Van Hemelrijck, Mieke
- Published
- 2022
- Full Text
- View/download PDF
3. Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic.
- Author
-
Monroy-Iglesias, Maria J., Russell, Beth, Martin, Sabine, Fox, Louis, Moss, Charlotte, Bruno, Flaminia, Millwaters, Juliet, Steward, Lindsay, Murtagh, Colette, Cargaleiro, Carlos, Bater, Darren, Lavelle, Grace, Simpson, Anna, Onih, Jemima, Haire, Anna, Reeder, Clare, Jones, Geraint, Smith, Sue, Santaolalla, Aida, and Van Hemelrijck, Mieke
- Subjects
MENTAL depression ,ANXIETY ,MACHINE learning ,CANCER patients ,ANXIETY disorders ,SUPPORT vector machines - Abstract
Background: Rapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy's and St Thomas' Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression. Methods: Patients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables. Results: A total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36-4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28-3.77), weight loss (AOR 1.88; 95% CI 1.362.61), progressive pain (AOR 1.71; 95%CI 1.26-2.32), and fatigue (AOR 1.36; 95%CI 1.01-1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17-5.75), fatigue (AOR 2.11; 95%CI 1.47-3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06-3.68), weight loss (AOR 1.66; 95%CI 1.13-2.44), and progressive pain (AOR 1.50; 95%CI 1.04-2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%). Conclusion: High prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis.
- Author
-
Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, and Tolani, Musliu Adetola
- Abstract
While previous reviews found a positive association between pre‐existing cancer diagnosis and COVID‐19‐related death, most early studies did not distinguish long‐term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher‐quality evidence on risk of COVID‐19‐related death for people with recent/active cancer (compared to people without) in the pre‐COVID‐19‐vaccination period. We searched the WHO COVID‐19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk‐of‐bias assessment was based on the Newcastle‐Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse‐variance random‐effects models. Random‐effects meta‐regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID‐19‐related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36‐1.61, I2 = 0; people with COVID‐19: aOR = 1.58, 95% CI: 1.41‐1.77, I2 = 0.58; inpatients with COVID‐19: aOR = 1.66, 95% CI: 1.34‐2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4‐4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68‐2.68, I2 = 0.43), and for metastatic cancers. Meta‐regression suggested risk of COVID‐19‐related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37‐1.75) at 1 year and aOR = 0.98 (95% CI: 0.80‐1.20) at 5 years post‐cancer diagnosis/treatment. In conclusion, before COVID‐19‐vaccination, risk of COVID‐19‐related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis
- Author
-
Steinberg, Julia, primary, Hughes, Suzanne, additional, Hui, Harriet, additional, Allsop, Matthew J., additional, Egger, Sam, additional, David, Michael, additional, Caruana, Michael, additional, Coxeter, Peter, additional, Carle, Chelsea, additional, Onyeka, Tonia, additional, Rewais, Isabel, additional, Monroy Iglesias, Maria J., additional, Vives, Nuria, additional, Wei, Feixue, additional, Abila, Derrick Bary, additional, Carreras, Giulia, additional, Santero, Marilina, additional, O'Dowd, Emma L., additional, Lui, Gigi, additional, Tolani, Musliu Adetola, additional, Mullooly, Maeve, additional, Lee, Shing Fung, additional, Landy, Rebecca, additional, Hanley, Sharon J. B., additional, Binefa, Gemma, additional, McShane, Charlene M., additional, Gizaw, Muluken, additional, Selvamuthu, Poongulali, additional, Boukheris, Houda, additional, Nakaganda, Annet, additional, Ergin, Isil, additional, Moraes, Fabio Ynoe, additional, Timilshina, Nahari, additional, Kumar, Ashutosh, additional, Vale, Diama B., additional, Molina‐Barceló, Ana, additional, Force, Lisa M., additional, Campbell, Denise Joan, additional, Wang, Yuqing, additional, Wan, Fang, additional, Baker, Anna‐Lisa, additional, Singh, Ramnik, additional, Salam, Rehana Abdus, additional, Yuill, Susan, additional, Shah, Richa, additional, Lansdorp‐Vogelaar, Iris, additional, Yusuf, Aasim, additional, Aggarwal, Ajay, additional, Murillo, Raul, additional, Torode, Julie S., additional, Kliewer, Erich V., additional, Bray, Freddie, additional, Chan, Kelvin K. W., additional, Peacock, Stuart, additional, Hanna, Timothy P., additional, Ginsburg, Ophira, additional, Van Hemelrijck, Mieke, additional, Sullivan, Richard, additional, Roitberg, Felipe, additional, Ilbawi, André M., additional, Soerjomataram, Isabelle, additional, and Canfell, Karen, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre
- Author
-
Monroy-Iglesias, Maria J, primary, Tremble, Kathryn, additional, Russell, Beth, additional, Moss, Charlotte, additional, Dolly, Saoirse, additional, Sita-Lumsden, Ailsa, additional, Cortellini, Alessio, additional, Pinato, David James, additional, Rigg, Anne, additional, Karagiannis, Sophia N, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic
- Author
-
Hadi, Hajer, primary, Handford, Jasmine, additional, Russell, Beth, additional, Moss, Charlotte L, additional, Monroy Iglesias, Maria J, additional, Rammant, Elke, additional, Smith, Sue, additional, Dolly, Saoirse, additional, Thillai, Kiruthikah, additional, Rigg, Anne, additional, and Hemelrijck, Mieke Van, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Antibodies as biomarkers for cancer risk: a systematic review
- Author
-
Monroy-Iglesias, Maria J, primary, Crescioli, Silvia, additional, Beckmann, Kerri, additional, Le, Nga, additional, Karagiannis, Sophia N, additional, Van Hemelrijck, Mieke, additional, and Santaolalla, Aida, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Additional file 1 of Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19
- Author
-
So, Alfred Chung Pui, Karampera, Christina, Khan, Muhammad, Russell, Beth, Moss, Charlotte, Monroy-Iglesias, Maria J., Thillai, Kiruthikah, Josephs, Debra Hannah, Pintus, Elias, Rudman, Sarah, Van Hemelrijck, Mieke, Dolly, Saoirse, and Enting, Deborah
- Subjects
endocrine system ,endocrine system diseases ,urogenital system ,urologic and male genital diseases - Abstract
Additional file 1: Table S1. Patient demographics of prostate, renal, urothelial, and testicular cancer groups. Table S2. Oncological characteristics of prostate, renal, urothelial, and testicular cancer groups.
- Published
- 2022
- Full Text
- View/download PDF
10. Impact of the COVID‐19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan
- Author
-
Monroy‐Iglesias, Maria J., primary, Rai, Sonpreet, additional, Mistretta, Francesco A., additional, Roberts, Graham, additional, Dickinson, Harvey, additional, Russell, Beth, additional, Moss, Charlotte, additional, De Berardinis, Rita, additional, Ferro, Matteo, additional, Musi, Gennaro, additional, Brown, Christian, additional, Nair, Rajesh, additional, Thurairaja, Ramesh, additional, Fernando, Archana, additional, Cathcart, Paul, additional, Khan, Azhar, additional, Dasgupta, Prokar, additional, Malde, Sachin, additional, Hadijpavlou, Marios, additional, Dolly, Saoirse, additional, Haire, Kate, additional, Tagliabue, Marta, additional, de Cobelli, Ottavio, additional, Challacombe, Ben, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Safe Provision of Systemic Anti-Cancer Treatment for Urological Cancer Patients During COVID-19: A Tertiary Centre Experience in the First Wave of COVID-19
- Author
-
So, Alfred Chung Pui, primary, Karampera, Christina, additional, Khan, Muhammad, additional, Russell, Beth, additional, Moss, Charlotte, additional, Monroy-Iglesias, Maria J, additional, Thillai, Kiruthikah, additional, Josephs, Debra Hannah, additional, Pintus, Elias, additional, Rudman, Sarah, additional, Hemelrijck, Mieke, additional, Dolly, Saoirse, additional, and Enting, Deborah, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis
- Author
-
Monroy-Iglesias, Maria J., primary, Moss, Charlotte, additional, Beckmann, Kerri, additional, Hammar, Niklas, additional, Walldius, Goran, additional, Bosco, Cecilia, additional, Hemelrijck, Mieke Van, additional, and Santaolalla, Aida, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Development and outcomes of a virtual triage pathway for cancer diagnosis in vague symptom patients.
- Author
-
Tremble, Kathryn, primary, Monroy-Iglesias, Maria J., additional, Martin, Sabine, additional, Jones, Geraint, additional, Moss, Charlotte, additional, Russell, Beth, additional, Steward, Lindsay, additional, Murtagh, Colette, additional, Cargaleiro, Carlos, additional, Roberts, Graham, additional, Van Hemelrijck, Mieke, additional, De Michele, Luigi, additional, and Dolly, Saoirse, additional
- Published
- 2021
- Full Text
- View/download PDF
14. The impact of COVID-19 on delivery of systemic anti-cancer treatment in urological cancer patients: A comparison with 2019 data from Guy’s Cancer Center.
- Author
-
Karampera, Christina, primary, Khan, Muhammad, additional, Russell, Beth, additional, Moss, Charlotte, additional, Monroy-Iglesias, Maria J, additional, Dolly, Saoirse, additional, Thillai, Kiruthikah, additional, Josephs, Debra Hannah, additional, Pintus, Elias, additional, Rudman, Sarah, additional, Van Hemelrijck, Mieke, additional, and Enting, Deborah, additional
- Published
- 2021
- Full Text
- View/download PDF
15. Limb volume reduction and infection outcomes following vascularized lymph node transfer for cancer treatment-related lymphoedema: A systematic review and meta-analysis.
- Author
-
Ward, Joseph Alexander, primary, King, Ian CC, additional, Monroy-Iglesias, Maria J, additional, Russell, Beth, additional, Van Hemelrijck, Mieke, additional, Ramsey, Kelvin, additional, and Khan, Aadil A, additional
- Published
- 2021
- Full Text
- View/download PDF
16. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
- Author
-
Russell, Beth, primary, Moss, Charlotte L., additional, Palmer, Kieran, additional, Sylva, Rushan, additional, D’Souza, Andrea, additional, Wylie, Harriet, additional, Haire, Anna, additional, Cahill, Fidelma, additional, Steel, Renee, additional, Hoyes, Angela, additional, Wilson, Isabelle, additional, Macneil, Alyson, additional, Shifa, Belul, additional, Monroy-Iglesias, Maria J, additional, Papa, Sophie, additional, Irshad, Sheeba, additional, Ross, Paul, additional, Spicer, James, additional, Kordasti, Shahram, additional, Crawley, Danielle, additional, Zaki, Kamarul, additional, Sita-Lumsden, Ailsa, additional, Josephs, Debra, additional, Enting, Deborah, additional, Swampillai, Angela, additional, Sawyer, Elinor, additional, Fields, Paul, additional, Wrench, David, additional, Rigg, Anne, additional, Sullivan, Richard, additional, Van Hemelrijck, Mieke, additional, and Dolly, Saoirse, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies
- Author
-
Monroy-Iglesias, Maria J., primary, Dolly, Saoirse, additional, Sarker, Debashis, additional, Thillai, Kiruthikah, additional, Van Hemelrijck, Mieke, additional, and Santaolalla, Aida, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan
- Author
-
Monroy-Iglesias, Maria J., primary, Tagliabue, Marta, additional, Dickinson, Harvey, additional, Roberts, Graham, additional, De Berardinis, Rita, additional, Russell, Beth, additional, Moss, Charlotte, additional, Irwin, Sophie, additional, Olsburgh, Jonathon, additional, Cocco, Ivana Maria Francesca, additional, Schizas, Alexis, additional, McCrindle, Sarah, additional, Nath, Rahul, additional, Brunet, Aina, additional, Simo, Ricard, additional, Tornari, Chrysostomos, additional, Srinivasan, Parthi, additional, Prachalias, Andreas, additional, Davies, Andrew, additional, Geh, Jenny, additional, Fraser, Stephanie, additional, Routledge, Tom, additional, Ma, RuJun, additional, Doerge, Ella, additional, Challacombe, Ben, additional, Nair, Raj, additional, Hadjipavlou, Marios, additional, Scarpinata, Rosaria, additional, Sorelli, Paolo, additional, Dolly, Saoirse, additional, Mistretta, Francesco Alessandro, additional, Musi, Gennaro, additional, Casiraghi, Monica, additional, Aloisi, Alessia, additional, Dell’Acqua, Andrea, additional, Scaglione, Donatella, additional, Zanoni, Stefania, additional, Rampazio Da Silva, Daniele, additional, Brambilla, Daniela, additional, Bertolotti, Raffaella, additional, Peruzzotti, Giulia, additional, Maggioni, Angelo, additional, de Cobelli, Ottavio, additional, Spaggiari, Lorenzo, additional, Ansarin, Mohssen, additional, Mastrilli, Fabrizio, additional, Gandini, Sara, additional, Jain, Urvashi, additional, Hamed, Hisham, additional, Haire, Kate, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death
- Author
-
Monroy-Iglesias, Maria J., primary, Russell, Beth, additional, Moss, Charlotte, additional, George, Gincy, additional, Palmer, Kieran, additional, Papa, Sophie, additional, Irshad, Sheeba, additional, Ross, Paul, additional, Spicer, James, additional, Kordasti, Sharam, additional, Crawley, Danielle, additional, Wylie, Harriet, additional, Cahill, Fidelma, additional, Haire, Anna, additional, Sylva, Rushan, additional, Zaki, Kamarul, additional, Rahman, Fareen, additional, Sita-Lumsden, Ailsa, additional, Josephs, Debra, additional, Enting, Deborah, additional, Lei, Mary, additional, Ghosh, Sharmistha, additional, Harrison, Claire, additional, Swampillai, Angela, additional, Sawyer, Elinor, additional, D'Souza, Andrea, additional, Gomberg, Simon, additional, Fields, Paul, additional, Wrench, David, additional, Raj, Kavita, additional, Gleeson, Mary, additional, Bailey, Kate, additional, Dillon, Richard, additional, Streetly, Matthew, additional, Kulasekararaj, Austin, additional, Ko, Thinzar Ko, additional, Shah, Vallari, additional, Rigg, Anne, additional, Sullivan, Richard, additional, Van Hemelrijck, Mieke, additional, and Dolly, Saoirse, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank
- Author
-
Monroy‐Iglesias, Maria J., primary, Russell, Beth, additional, Crawley, Danielle, additional, Allen, Naomi E., additional, Travis, Ruth C., additional, Perez‐Cornago, Aurora, additional, Van Hemelrijck, Mieke, additional, and Beckmann, Kerri, additional
- Published
- 2020
- Full Text
- View/download PDF
21. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
- Author
-
Russell, Beth, Moss, Charlotte L., Shah, Vallari, Ko, Thinzar Ko, Palmer, Kieran, Sylva, Rushan, George, Gincy, Monroy-Iglesias, Maria J., Patten, Piers, Ceesay, Muhammed Mansour, Benjamin, Reuben, Potter, Victoria, Pagliuca, Antonio, Papa, Sophie, Irshad, Sheeba, Ross, Paul, Spicer, James, Kordasti, Shahram, Crawley, Danielle, and Wylie, Harriet
- Abstract
Background: Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death. Methods: Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality. Results: Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR): 1.97 (95% confidence interval (CI): 1.15–3.38)], Asian ethnicity [3.42 (1. 59–7.35)], haematological cancer [2.03 (1.16–3.56)] and a cancer diagnosis for >2–5 years [2.81 (1.41–5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis). Conclusions: Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank.
- Author
-
Monroy‐Iglesias, Maria J., Russell, Beth, Crawley, Danielle, Allen, Naomi E., Travis, Ruth C., Perez‐Cornago, Aurora, Van Hemelrijck, Mieke, and Beckmann, Kerri
- Subjects
SOMATOMEDIN C ,METABOLIC syndrome ,DYSLIPIDEMIA ,PROSTATE cancer ,BIOMARKERS ,TYPE 2 diabetes ,GLYCOSYLATED hemoglobin - Abstract
We investigated the association between metabolic syndrome (MetS) and its components and risk of prostate cancer (PCa) in a cohort of men enrolled in the UK Biobank. Our study cohort included 220 622 PCa‐free men with baseline measurements of triglycerides (TGs), HDL‐cholesterol (HDL), glycated hemoglobin (HbA1c), blood pressure (BP), and waist circumference (WC). Multivariable Cox proportional hazards regression was used to analyze associations with PCa for: individual metabolic components (TG, HDL, HbA1c, BP, WC), combinations of two and three components, and MetS overall (three or more components). We conducted mediation analyses to examine potential hormonal and inflammatory pathways (total testosterone [TT], C‐reactive protein [CRP], insulin‐like growth factor 1 [IGF‐1]) through which MetS components may influence PCa risk. A total of 5409 men in the study developed PCa during a median follow‐up of 6.9 years. We found no significant association between MetS and PCa risk (hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.92‐1.06). No associations were found with PCa risk and individual measurements of TG, HDL, BP, or WC. However, an inverse association was observed with elevated HbA1c (≥42 mmol/mol) (HR = 0.89, 95% CI = 0.79‐0.98). Consistent inverse associations were observed between HbA1c and risk of PCa. Mediation analysis revealed TT, CRP, and IGF‐1 as potential mediating factors for this association contributing 10.2%, 7.1%, and 7.9% to the total effect, respectively. Overall MetS had no association with PCa risk. However, a consistent inverse association with PCa risk was found for HbA1c. This association may be explained in part through hormonal and inflammatory pathways. What's new? Risk of prostate cancer is variously linked to obesity, type 2 diabetes mellitus, and other components of metabolic syndrome (MetS). Evidence for a clear association between prostate cancer and MetS and its components, however, remains elusive. In this large, prospective study, the authors found that MetS is not significantly associated with risk of prostate cancer. Glycated hemoglobin (HbA1c), however, was found to be inversely associated with risk. Analyses examining potential hormonal and inflammatory pathways identified total testosterone, C‐reactive protein, and insulin‐like growth factor 1 as potential mediating factors for the association between HbA1c and prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Antibodies as biomarkers for cancer risk: a systematic review
- Author
-
Maria J Monroy-Iglesias, Silvia Crescioli, Kerri Beckmann, Nga Le, Sophia N Karagiannis, Mieke Van Hemelrijck, Aida Santaolalla, Monroy-Iglesias, Maria J, Crescioli, Silvia, Beckmann, Kerri, Le, Nga, Karagiannis, Sophia N, Van Hemelrijck, Mieke, and Santaolalla, Aida
- Subjects
Immunology ,biomarkers ,Enzyme-Linked Immunosorbent Assay ,Immunoglobulin E ,Immunoglobulin A ,Immunoglobulin M ,Immunoglobulin G ,Neoplasms ,antibodies ,cancer ,Humans ,Immunology and Allergy ,tumor-associated antigens ,early detection ,immunoglobulin ,Biomarkers ,Autoantibodies - Abstract
Increasing evidence has linked the humoral immune response with the development of various cancers. Therefore, there is growing interest in investigating the predictive value of antibodies to assess overall and tissue site-specific cancer risk. Given the large amount of antibody types and the broad scope of the search (i.e. cancer risk), the primary aim of this systematic review was to present an overview of the most researched antibodies (i.e. immunoglobulin (Ig) isotypes (IgG, IgM, IgA, and IgE), tumour and self-antigen-reactive antibodies, infection-related antibodies) in relation to overall and site-specific cancer risk. We identified various antibody types that have been associated with the risk of cancer. While no significant associations were found for IgM serum levels, studies found an inconsistent association among IgE, IgA, and IgG serum levels in relation to cancer risk. When evaluating antibodies against infectious agents, most studies reported a positive link with specific cancers known to be associated with the specific agent recognized by serum antibodies (i.e. helicobacter pylori and gastric cancer, hepatitis B virus and hepatocellular carcinoma, and human papillomavirus and cervical cancer). Several reports identified autoantibodies, as single biomarkers (e.g. anti-p53, anti-MUC1, and anti-CA125) but especially in panels of multiple autoantibodies, to have potential as diagnostic biomarkers for specific cancer types. Overall, there is emerging evidence associating certain antibodies to cancer risk, especially immunoglobulin isotypes, tumour-associated antigen-specific, and self-reactive antibodies. Further experimental studies are necessary to assess the efficacy of specific antibodies as markers for the early diagnosis of cancer.
- Published
- 2022
24. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank
- Author
-
Maria J. Monroy‐Iglesias, Beth Russell, Danielle Crawley, Naomi E. Allen, Ruth C. Travis, Aurora Perez‐Cornago, Mieke Van Hemelrijck, Kerri Beckmann, Monroy-Iglesias, Maria J, Russell, Beth, Crawley, Danielle, Allen, Naomi E, Travis, Ruth C, Perez-Cornago, Aurora, Van Hemelrijck, Mieke, and Beckmann, Kerri
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,Inverse Association ,medicine.medical_specialty ,Waist ,Blood Pressure ,metabolic syndrome ,Cohort Studies ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Testosterone ,mediation analysis ,Triglycerides ,Aged ,Biological Specimen Banks ,Proportional Hazards Models ,Glycated Hemoglobin ,Metabolic Syndrome ,business.industry ,Cholesterol, HDL ,Hazard ratio ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,prostate cancer ,United Kingdom ,Confidence interval ,C-Reactive Protein ,chemistry ,030220 oncology & carcinogenesis ,Cohort ,Glycated hemoglobin ,Waist Circumference ,Metabolic syndrome ,business ,Biomarkers ,glycated hemoglobin - Abstract
We investigated the association between metabolic syndrome (MetS) and its components and risk of prostate cancer (PCa) in a cohort of men enrolled in the UK Biobank. Our study cohort included 220 622 PCa‐free men with baseline measurements of triglycerides (TG), HDL‐cholesterol (HDL), glycated haemoglobin (HbA1c), blood pressure (BP), and waist circumference (WC). Multivariable Cox proportional hazards regression was used to analyse associations with PCa for: individual metabolic components (TG, HDL, HbA1c, BP, WC), combinations of two and three components, and MetS overall (three or more components). We conducted mediation analyses to examine potential hormonal and inflammatory pathways (total testosterone (TT), C‐reactive protein (CRP), insulin‐like growth factor 1 (IGF‐1)) through which MetS components may influence PCa risk. A total of 5409 men in the study developed PCa during a median follow‐up of 6.9 years. We found no significant association between MetS and PCa risk (Hazard Ratio (HR): 0.99, 95% Confidence Interval (CI): 0.92‐1.06). No associations were found with PCa risk and individual measurements of TG, HDL, BP or WC. However, an inverse association was observed with elevated HbA1c (≥42 mmol/mol) (HR: 0.89, 95%CI: 0.79‐0.98). Consistent inverse associations were observed between HbA1c and risk of PCa. Mediation analysis revealed TT, CRP and IGF‐1 as potential mediating factors for this association contributing 10.2%, 7.1% and 7.9% to the total effect, respectively. Overall MetS had no association with PCa risk. However, a consistent inverse association with PCa risk was found for HbA1c. This association may be explained in part through hormonal and inflammatory pathways.
- Published
- 2021
25. Serum total bilirubin and risk of cancer: a Swedish cohort study and meta‐analysis
- Author
-
Maria J. Monroy-Iglesias, Niklas Hammar, Charlotte Moss, Göran Walldius, Kerri Beckmann, Aida Santaolalla, Cecilia Bosco, Mieke Van Hemelrijck, Monroy Iglesias, Maria J, Moss, Charlotte, Beckmann, Kerri, Hammar, Niklas, Walldius, Goran, Bosco, Cecilia, Van Hemelrijck, Mieke, and Santaolalla, Aida
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,hyperbilirubinemia ,Colorectal cancer ,colorectal cancer ,cancer risk ,Article ,Breast cancer ,breast cancer ,Internal medicine ,medicine ,cohort study ,melanoma ,Lung cancer ,RC254-282 ,business.industry ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,gynecological cancer ,medicine.disease ,lung cancer ,Relative risk ,Cohort ,bilirubin ,Risk assessment ,business ,Cohort study - Abstract
Bilirubin has strong antioxidant properties that have been hypothesized to be preventive against the development of cancer. Thus, we aimed to investigate the association between serum total bilirubin (STB) and risk of overall and site-specific cancers in the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort. We also performed a systematic review and meta-analysis for specific cancer types (colorectal, breast and lung). We found no association between high levels of STB and risk of overall cancer. Regarding site-specific cancer, there was an inverse association between increased STB and lung cancer (Hazard Ratio (HR) for the 4th quartile (Q4) vs. Q1: 0.50, 95%CI: 0.44–0.59) and gynecological cancer (HR for Q4 vs. Q1: 0.86, 95%CI: 0.76–0.99). A positive association was found with melanoma (HR for Q4 vs. Q1: 1.25, 95%CI: 1.06–1.47) and breast cancer (HR for Q4 vs. Q1: 1.13, 95%CI: 1.01–1.25) risk. The meta-analysis showed an inverse association between high levels of STB and risk of lung cancer (Relative risk (RR): 0.69, 95%CI: 0.55–0.86). No associations were seen for colorectal and breast cancer risk. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.